Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy is licensed as a once-weekly injection, not twice a week. Each dose delivers semaglutide across a full seven days, and doubling up does not increase the medicine's benefit — it significantly raises the risk of side effects. If a dose has been missed or a pen has misfired, the answer is not a second injection that same week. As a prescription-only medicine, Wegovy's schedule is set by your prescriber and the NHS patient information for semaglutide is clear: one injection per week, on the same day each time.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It is a logical thought. Weight loss feels urgent, and if one injection helps, surely two would help more. In practice, semaglutide does not work that way. The molecule is engineered to bind to GLP-1 receptors and remain active for roughly seven days. By day eight, the previous dose is clearing, which is exactly why the prescribing schedule is a fixed weekly interval. Front-loading two doses into the same week does not double the signal sent to your appetite centres; it swamps a system already at capacity.
Clinical trial evidence for Wegovy (including the STEP 1 study published in the New England Journal of Medicine) was built on strict once-weekly dosing. The 15% average weight reduction seen over 68 weeks at the 2.4 mg maintenance dose reflects that schedule, not an accelerated one. Straying from it doesn't replicate those results; it trades them for avoidable side effects.
If the idea has crossed your mind because progress feels slower than expected, that is worth raising with your prescriber at your next review, not resolving with an extra pen.
Semaglutide slows gastric emptying and acts on appetite signals in the brain. Both effects are dose-dependent. When two doses land within seven days, the body is effectively receiving a far higher concentration than the licensed dose, and the gastrointestinal system bears the brunt of it.
Nausea is already the most commonly reported side effect during the early stages of treatment. A second injection in the same week can make this considerably worse, expect more intense nausea, a greater likelihood of vomiting, and the kind of fatigue that follows significant GI upset. Dehydration becomes a real concern if vomiting is prolonged, and for some people that chain of events leads to the need for medical attention.
The NHS England guidance on weight management injections is consistent: semaglutide should be taken once per week. It does not suggest any circumstance where a second same-week dose is appropriate. If you have already injected twice in one week and are feeling unwell, contact your prescriber or call 111.
One practical check that takes under a minute: look at the date written on or stored with your last used pen, or check the injection reminder on your phone. If seven days have not passed, the answer is to wait, not inject again.
Two common situations lead people to consider injecting a second time. The first is a genuine missed dose. The second is uncertainty about whether a pen actually delivered its dose, a worry our prescribers hear regularly about pens that didn't seem to click twice.
For a missed dose, the decision rests on timing. If fewer than five days have passed since you were due to inject, take the missed dose as soon as you remember, then return to your normal weekly day. If more than five days have passed, skip that dose entirely and resume on the next scheduled day. Never take two doses to make up for one missed. This mirrors the standard guidance in the Patient Information Leaflet supplied with your pen, it is worth reading that leaflet, not relying on memory.
For pen uncertainty, the instinct to inject again is understandable but carries the same risk as a deliberate double dose. If you are unsure whether your Wegovy pen delivered its dose, contact your prescriber before injecting again. A visual check of the pen's dose window and the leaflet's instructions can often resolve the question without the need for a second injection.
Questions about injection technique more broadly (including which sites are suitable for your Wegovy injection and how to rotate them) are genuinely worth discussing with a clinician, particularly early in treatment when everything about the process is new. There is no such thing as a silly question when it involves a prescription medicine and your health.
Wegovy works best when its dosing schedule is followed consistently and titrated carefully by a prescriber. The escalation from 0.25 mg through to the maintenance dose exists to let your body adjust gradually, and if you are wondering whether it is safe to inject semaglutide twice a week, skipping ahead or doubling up short-circuits that process and the clinical rationale behind it.
If you are finding the schedule confusing, having side effects that make you want to skip doses, or wondering whether Wegovy is the right treatment for you at all, those are conversations for your clinical team. You can read more about what happens to your body if you take semaglutide twice a week on a dedicated page, and if cost or access questions are on your mind, our Wegovy price comparison guide covers what UK private treatment typically involves.
Wegovy is a prescription medicine reviewed by a real clinician before and during treatment. At nume, every repeat order goes back to a GPhC-registered prescriber for assessment, not an automated system. If your current schedule or dose is not working for you, the right next step is a clinical conversation. Speak to our prescribers and get advice grounded in your actual situation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.